Therapeutic Equivalence | List of Frontiers open access articles

Brief Research Report

Published on 22 Feb 2023

Does China’s competitive generic substitution policy deliver equivalent clinical outcomes? A pilot study with two generic formulations of olanzepine

in Drugs Outcomes Research and Policies

Chao Zhang
Yudan Ding
Zhenzhen Wu
Juan Wang
Xiangping Wu
Weiwei Xie

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1097600

3,853 views
2 citations

Policy and Practice Reviews

Published on 11 Sep 2020

The “Square Box”: Therapeutic Equivalence as a Foundation of the WHO Model List of Essential Medicines

in Drugs Outcomes Research and Policies

Bernadette Cappello
Lorenzo Moja
Albert Figueras
Nicola Magrini

Frontiers in Pharmacology

doi 10.3389/fphar.2020.578000

6,927 views
12 citations

Review

Published on 23 Nov 2020

Non-biological Complex Drugs (NBCDs): Complex Pharmaceuticals in Need of Individual Robust Clinical Assessment Before Any Therapeutic Equivalence Decision

in Regulatory Science

Rogério Sá Gaspar
Beatriz Silva-Lima
Fernando Magro
Armando Alcobia
Fernando Leal da Costa
José Feio

Frontiers in Medicine

doi 10.3389/fmed.2020.590527

14,443 views
36 citations

Perspective

Published on 18 Apr 2024

Generic orphan drug substitution: a critical analysis of global practices and Saudi Arabia’s perspective

in Pharmacoepidemiology

Yousif S. Alakeel
Emmanouil Rampakakis
Ali AlRumaih
Rana AlRuwaisan
Maha Abushal
Abdullah M. AlDalaan
Majdy M. Idrees
Zaid D. Alanazi
Hanouf AlKoait
Abdulrahman Muaadi

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1376009

4,147 views

Original Research

Published on 12 May 2025

Comparative analysis of Erycibe schmidtii Craib and its potential substitutes based on metabolites and pharmacodynamic effect

in Ethnopharmacology

Ning Li
Chen-Yu Ye
Jing Hu
Tong Qu
Wen-Jing Lu
Xiao-Min Cui
Chao Liang
Zhi-Yong Chen
Hui Ren
Chang-Jiang-Sheng Lai

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1510170

2,342 views

Original Research

Published on 13 Jun 2022

Real-World Impact of Switching From Insulin Glargine (Lantus®) to Basaglar® and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia

in Health Economics

Yazed AlRuthia
Ohud H. Bahari
Suliman Alghnam
Ali M. Alrumaih
Hassan Asiri
Mohammed Alshammari
Mansour Alhowimel
Hana A. Al-Abdulkarim

Frontiers in Public Health

doi 10.3389/fpubh.2022.852721

10,386 views
10 citations

Articles

Does China’s competitive generic substitution policy deliver equivalent clinical outcomes? A pilot study with two generic formulations of olanzepine

The “Square Box”: Therapeutic Equivalence as a Foundation of the WHO Model List of Essential Medicines

Non-biological Complex Drugs (NBCDs): Complex Pharmaceuticals in Need of Individual Robust Clinical Assessment Before Any Therapeutic Equivalence Decision

Generic orphan drug substitution: a critical analysis of global practices and Saudi Arabia’s perspective

Comparative analysis of Erycibe schmidtii Craib and its potential substitutes based on metabolites and pharmacodynamic effect

Real-World Impact of Switching From Insulin Glargine (Lantus®) to Basaglar® and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia